Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...

The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The 2025 Warren Alpert Foundation Prize has been awarded to three scientists whose discoveries culminated in the development ...

Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo. In clinical ...

WHO celebrates FDA's nod to injectable lenacapavir for HIV prevention, promising easier adherence with biannual doses.

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.